IO Biotech Files 8-K: Bankruptcy, Financial Obligations, Officer Changes
Ticker: IOBT · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: bankruptcy, financial-distress, corporate-governance
TL;DR
IO Biotech is in deep trouble, filing for bankruptcy and facing accelerated debt.
AI Summary
IO Biotech, Inc. filed an 8-K on March 31, 2026, reporting on several key events. These include potential bankruptcy or receivership proceedings, triggering events that could accelerate financial obligations, and changes related to directors or officers. The company also disclosed other events not covered by the standard items.
Why It Matters
This filing indicates significant financial distress and potential operational changes for IO Biotech, Inc., which could impact its ongoing research, development, and future viability.
Risk Assessment
Risk Level: high — The filing explicitly mentions bankruptcy or receivership, signaling severe financial distress and a high risk of failure.
Key Players & Entities
- IO Biotech, Inc. (company) — Filer of the 8-K report
- 0001865494 (company) — CIK number for IO Biotech, Inc.
- 2026-03-31 (date) — Filing date and period of report
FAQ
What specific events are triggering the acceleration or increase of IO Biotech's financial obligations?
The filing does not specify the exact triggering events but lists Item 2.04 as a relevant disclosure.
Are there any new directors or officers appointed or departing from IO Biotech?
Yes, Item 5.02 of the filing addresses the departure of directors or certain officers, election of directors, and appointment of certain officers.
What is the nature of the 'Other Events' disclosed in Item 8.01?
The filing does not provide details on the specific 'Other Events' beyond listing the item number.
Is IO Biotech currently in bankruptcy or receivership proceedings?
Item 1.03 of the filing pertains to Bankruptcy or Receivership, indicating this is a subject of the report.
What is the business address of IO Biotech, Inc.?
The business address is OLE MAALOES VEH 3 COPENHAGEN G7 2200.
Filing Stats: 934 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2026-03-31 08:00:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share IOBT The Nasdaq
Filing Documents
- d87973d8k.htm (8-K) — 28KB
- 0001193125-26-133331.txt ( ) — 140KB
- iobt-20260331.xsd (EX-101.SCH) — 3KB
- iobt-20260331_lab.xml (EX-101.LAB) — 17KB
- iobt-20260331_pre.xml (EX-101.PRE) — 11KB
- d87973d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IO Biotech, Inc. Date: March 31, 2026 By: /s/ Mai-Britt Zocca Mai-Britt Zocca, Ph.D. Chief Executive Officer